Open an account Help & support Register Account summary Log out
Skip Header
Home Stock market news

Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Director dealings: Creo Medical board members add to holdings

Fri 27 May 2022 11:30

(Sharecast News) - Creo Medical Group had several entries on the list of director buys on Friday, after it disclosed three share purchases made by two of its board members. The AIM-traded firm said non-executive chairman Charles Spicer purchased 15,435 shares at a price of 97.18p each, spending a total of £14,999.73.

Following the transaction, Spicer's total direct interest in the company held via his self-invested personal pension was now 143,411 shares, representing 0.08% of its issued capital.

Chief financial officer Richard Rees, meanwhile, purchased a total of 70,000 shares at a price of 96.75p apiece.

It said Rees purchased 21,400 of those into his self-invested pension plan, for a total of £20,704.50, while the remaining 48,600 were purchased for a total value of £47,020.50.

Creo said Rees' total direct interest in the company was now 73,615 shares, representing 0.04% of its issued capital.

Reporting by Josh White at Sharecast.com.

Top Director Buys

I3 Energy (I3E) Director name: Festival,John Amount purchased: 354,500 @ $0.44 Value: $91,230.90

Surface Transforms (SCE) Director name: Cleminson,Ian Amount purchased: 102,053 @ 49.00p Value: £50,005.97

Bakkavor Group (BAKK) Director name: Lodge ,Jane Ann Amount purchased: 50,000 @ 100.00p Value: £50,000.00

Smithson Investment Trust (SSON) Director name: Bartlett,Diana Dyer Amount purchased: 3,886 @ 1,280.00p Value: £49,740.80

Creo Medical Group (CREO) Director name: Rees,Richard John Amount purchased: 48,600 @ 96.75p Value: £47,020.50

Creo Medical Group (CREO) Director name: Rees,Richard John Amount purchased: 21,400 @ 96.75p Value: £20,704.50

Creo Medical Group (CREO) Director name: Spicer,Charles Amount purchased: 15,435 @ 97.18p Value: £14,999.73

Share this article

Related Sharecast Articles

Thu 15 Oct 2026 14:36
Director dealings: British American Tobacco's Karen Guerra purchases shares
(Sharecast News) - British American Tobacco revealed on Thursday that non-executive director Karen Guerra had acquired 6,000 ordinary shares in the FTSE 100-listed tobacco giant.
Wed 14 Oct 2026 14:28
Director dealings: Convatec non-executive director makes share purchase
(Sharecast News) - Convatec revealed on Wednesday that non-executive director Jens Viebke had acquired 24,400 ordinary shares in the FTSE 100-listed medical products and technology firm.
Tue 13 Oct 2026 14:15
Director dealings: Mortgage Advice Bureau chairman snaps up shares
(Sharecast News) - Mortgage Advice Bureau revealed on Tuesday that non-executive chairman Michael Jones had acquired 5,833 ordinary shares in the AIM-listed property finance platform operator.
Mon 12 Oct 2026 13:08
Director dealings: Insig Ai CEO raises stake
(Sharecast News) - Insig Ai revealed on Monday at chief executive Richard Bernstein had acquired 400,000 ordinary shares in the AIM-listed data infrastructure and machine learning firm.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Awards

Award 1
Award 2
Award 3

Policies and important information

Accessibility | Conflicts of interest statement | Consumer Duty Target Market | Consumer Duty Value Assessment Statements | Cookie policy | Diversity, Equity & Inclusion | Diversity, Equity & Inclusion Reports | Doing Business with Fidelity | Investing in Fidelity funds | Legal information | Modern slavery | Mutual respect policy | Privacy statement | Remuneration policy | Statutory and Regulatory disclosures | Whistleblowing programme

Please remember that past performance is not necessarily a guide to future performance, the performance of investments is not guaranteed, and the value of your investments can go down as well as up, so you may get back less than you invest. When investments have particular tax features, these will depend on your personal circumstances and tax rules may change in the future. This website does not contain any personal recommendations for a particular course of action, service or product. You should regularly review your investment objectives and choices and, if you are unsure whether an investment is suitable for you, you should contact an authorised financial adviser. Before opening an account, please read the ‘Doing Business with Fidelity’ document which incorporates our client terms. Prior to investing into a fund, please read the relevant key information document or Product Summary document which contains important information about the fund.

This website is issued by Financial Administration Services Limited, which is authorised and regulated by the Financial Conduct Authority (FCA) (FCA Register number 122169) and registered in England and Wales under company number 1629709 whose registered address is Beech Gate, Millfield Lane, Lower Kingswood, Tadworth, Surrey, KT20 6RP.

© FIL Limited 2026